Categories: Health

Addex Therapeutics to Release Q1 2025 Financial Results and Host Conference Call on June 19, 2025

 | Source: Addex Therapeutics

Geneva, Switzerland, June 18, 2025 Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced that it will issue its Q1 2025 Financial Results on June 19, 2025. Tim Dyer, CEO and Mikhail Kalinichev, Head of Translational Science, will provide a business update and review of the Addex product pipeline during a teleconference and webcast for investors, analysts and media at 16:00 CEST (15:00 BST / 10:00 EDT / 07:00 PDT) the same day.

Title:   Addex Therapeutics Q1 2025 financial results and corporate update
Date: June 19, 2025
Time: 16:00 CEST (15:00 BST / 10:00 EDT / 07:00 PDT)

Joining the Conference Call:

  1. Participants are required to register in advance of the conference using the link provided below. Upon registering, each participant will be provided with Participant Dial-in numbers, and a unique Personal PIN.
  2. In the 10 minutes prior to the call’s start time, participants will need to use the conference access information provided in the e-mail received at the point of registering. Participants may also use the call me feature instead of dialing the nearest dial in number.

Webcast registration URL: https://edge.media-server.com/mmc/p/esgoorze

Conference call registration URL: https://register-conf.media-server.com/register/BI6cb9bb203334429a891b86017ad16a73

About Addex Therapeutics

Addex Therapeutics is a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders. Addex’s lead drug candidate, dipraglurant (mGlu5 negative allosteric modulator or NAM), is under evaluation for future development in brain injury recovery, including post-stroke and traumatic brain injury recovery. Addex’s partner, Indivior, has selected a GABAB PAM drug candidate for development in substance use disorders and has successfully completed IND enabling studies. Addex is advancing an independent GABAB PAM program for chronic cough. Addex also holds a 20% equity interest in a private spin out company, Neurosterix LLC, which is advancing a portfolio of allosteric modulator programs, including M4 PAM for schizophrenia, mGlu7 NAM for mood disorders and mGlu2 NAM for mild neurocognitive disorders. Addex shares are listed on the SIX Swiss Exchange and American Depositary Shares representing its shares are listed on the NASDAQ Capital Market, and trade under the ticker symbol “ADXN” on each exchange. For more information, visit www.addextherapeutics.com
  
Contacts: 


Addex Forward Looking Statements:

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements about the intended use of proceeds of the offering. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release, are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, uncertainties related to market conditions. These and other risks and uncertainties are described in greater detail in the section entitled “Risk Factors” in Addex Therapeutics’ Annual Report on Form 20-F, prospectus and other filings that Addex Therapeutics may make with the SEC in the future. Any forward-looking statements contained in this press release represent Addex Therapeutics’ views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Addex Therapeutics explicitly disclaims any obligation to update any forward-looking statements.

GlobeNews Wire

Recent Posts

Clarifai Recognized as a Challenger and Fast Mover in GigaOm Radar for AI Infrastructure Report

WASHINGTON, July 24, 2025 /PRNewswire/ -- Clarifai, a global leader in AI and pioneer of…

10 hours ago

Antaisolar Ranks Among Top 9 in Global Solar Tracker Market Share, According to S&P Global

XIAMEN, China, July 24, 2025 /PRNewswire/ -- Recently, S&P Global, a leading authoritative data and…

10 hours ago

U.S. Exhibitors at 2025 CISCE Grow by 15%, Highlighting Strengthened Supply Chain Cooperation

BEIJING, July 25, 2025 /PRNewswire/ -- The third China International Supply Chain Expo (CISCE) was…

10 hours ago

Yali Capital Raises 893 Crores to Back India’s Deep Tech Revolution

BENGALURU, India, July 25, 2025 /PRNewswire/ -- Yali Capital, a SEBI-registered Category II Alternative Investment…

10 hours ago

Bureau Veritas Expands its Footprint in New Strongholds Through Acquisitions in Cybersecurity, Nuclear and Transition Services

PARIS--(BUSINESS WIRE)--Bureau Veritas, a global leader in Testing, Inspection, and Certification services (TIC), announces three…

11 hours ago

Almirall H1 2025 Results

Almirall Continues to Deliver on its Long-Term Growth Strategy with Net Sales Growth of 12.7%…

11 hours ago